The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
New 5-Aryl-Substituted 2-Aminobenzamide-Type HDAC Inhibitors with a Diketopiperazine Group and Their Ameliorating Effects on Ischemia-Induced Neuronal Cell Death
Open accessAbstract
We previously synthesized new 5-thienyl-substituted 2-aminobenzamide-type HDAC1, 2 inhibitors with the (4-ethyl-2,3-dioxopiperazine-1-carboxamido) methyl group. K-560 (1a) protected against neuronal cell death in a Parkinson’s disease model by up-regulating the expression of XIAP. This finding prompted us to design new K-560-related compounds. We examined the structure activity relationship (SAR) for the neuronal protective effects of newly synthesized and known K-560 derivatives after cerebral ischemia. Among them, K-856 (8), containing the (4-methyl-2,5-dioxopiperazin-1-yl) methyl group, exhibited a promising neuronal survival activity. The SAR study strongly suggested that the attachment of a monocyclic 2,3- or 2,5-diketopiperazine group to the 2-amino-5-aryl (but not 2-nitro-5-aryl) scaffold is necessary for K-560-related compounds to exert a potent neuroprotective effect.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While most HDACi tend to employ a hydroxamic acid as a ZBG, class I HDACs (particularly HDACs 1–3) tend to be the only class of HDACs inhibited by 2-amino anilides as a ZBG (Figure 4A) [9–13].”
From Medicinal chemistry advances in targeting class I histone deacetylases (2023) · cites this paper as [10]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Randomized Trial of Intraarterial Treatment for Acute Ischemic Stroke
Berkhemer, O. A., Fransen, P. S. S., Beumer, D., van den Berg, L. A., Lingsma, H. F., Yoo, A. J., Schonewille, W. J., Vos, J. A., Nederkoorn, P. J., Wermer, M. J. H., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411587 · Cited by 6,657
Randomized Assessment of Rapid Endovascular Treatment of Ischemic Stroke
Goyal, M., Demchuk, A. M., Menon, B. K., Eesa, M., Rempel, J. L., Thornton, J., Roy, D., Jovin, T. G., Willinsky, R. A., Sapkota, B. L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414905 · Cited by 6,083
Endovascular Therapy for Ischemic Stroke with Perfusion-Imaging Selection
Campbell, B. C. V., Mitchell, P. J., Kleinig, T. J., Dewey, H. M., Churilov, L., Yassi, N., Yan, B., Dowling, R. J., Parsons, M. W., Oxley, T. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414792 · Cited by 5,819
Stent-Retriever Thrombectomy after Intravenous t-PA vs. t-PA Alone in Stroke
Saver, J. L., Goyal, M., Bonafe, A., Diener, H.-C., Levy, E. I., Pereira, V. M., Albers, G. W., Cognard, C., Cohen, D. J., Hacke, W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1415061 · Cited by 5,193
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919 · cited 6×
“4B) and with OP-857 (9), OP-858 (10), OP-859 (11) (each at 1, 3 or 10 μM), 1a (at 0.”
BackgroundMethodInfluentialTreatment Strategies for Acute Ischemic Stroke Caused by Carotid Artery Occlusion
Li, W., Yin, Q., Xu, G., & Liu, X. (2016) · Interventional Neurology · doi:10.1159/000445304 · Cited by 2,319
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
Minucci, S., & Pelicci, P. G. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1779 · Cited by 2,200 · cited 8×
“This starting material was reacted with 4-ethyl-2,3-dioxo-1-piperazine, cyclo-L-prolylglycine, 1-methylpiperazine-2,5-dione, 1-methyl-piperazin-2-one, tert-butyl 3-oxopiperazine-1-carboxylate and 1-ethylpiperazine in the presence of sodium hydride (NaH) to yield the condensation products 6a, 7a, 8a, 9a, 10a and 11a, w…”
BackgroundMethodInfluentialSveinsson, O., Herrman, L., & Holmin, S. (2016) · Case Reports in Neurology · doi:10.1159/000452213 · Cited by 2,034
HDAC2 negatively regulates memory formation and synaptic plasticity
Guan, J.-S., Haggarty, S. J., Giacometti, E., Dannenberg, J.-H., Joseph, N., Gao, J., Nieland, T. J. F., Zhou, Y., Wang, X., Mazitschek, R., et al. (2009) · Nature · doi:10.1038/nature07925 · Cited by 1,644
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Falkenberg, K. J., & Johnstone, R. W. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4360 · Cited by 1,564
Research works printed but not linked: 1
- Uesato, S. & Hirata, Y. Proceedings of Frontiers in Medicinal Chemistry (FMC), P172, Antwerp, Belgium September 14–16 (2015).
Cited by
Milazzo, G., Mercatelli, D., Di Muzio, G., Triboli, L., De Rosa, P., Perini, G., & Giorgi, F. M. (2020) · Genes · doi:10.3390/genes11050556 · Cited by 423
Strategies To Design Selective Histone Deacetylase Inhibitors
Melesina, J., Simoben, C. V., Praetorius, L., Bülbül, E. F., Robaa, D., & Sippl, W. (2021) · ChemMedChem · doi:10.1002/cmdc.202000934 · Cited by 118
Targeting post-translational histone modifying enzymes in glioblastoma
Kunadis, E., Lakiotaki, E., Korkolopoulou, P. A., & Piperi, C. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107721 · Cited by 116
Current trends in development of HDAC-based chemotherapeutics
Cheshmazar, N., Hamzeh‐Mivehroud, M., Charoudeh, H. N., Hemmati, S., Melesina, J., & Dastmalchi, S. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120946 · Cited by 60
Targeting HDAC Complexes in Asthma and COPD
Zwinderman, M. R. H., de Weerd, S., & Dekker, F. J. (2019) · Epigenomes · doi:10.3390/epigenomes3030019 · Cited by 57
“Interestingly, aromatic substituents in position 4 lead to selective inhibition of HDAC1 and HDAC2 over HDAC3 [104,108,109].”
Background
Metadata
- Authors
- Hirata, Y., Sasaki, T., Kanki, H., Choong, C.-J., Nishiyama, K., Kubo, G., Hotei, A., Taniguchi, M., Mochizuki, H., & Uesato, S.
- Affiliations
- Kansai University (JP)
- The University of Osaka (JP)
- Osaka University of Pharmaceutical Sciences (JP)
- Corresponding author
- Sasaki, Tsutomu
- Uesato, Shinichi
- Venue
- Scientific Reports
- Published
- 2018-01-23
- Volume
- 8
- Issue
- 1
- Pages
- 1400-1400
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC5780423
- OpenAlex
- W2807656347
- Cited by
- 20
- References
- 50
- Citations by year
- 2024: 1 · 2023: 4 · 2022: 4 · 2021: 4 · 2020: 5 · 2019: 2
- FWCI
- 0.98
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Smoking Research Foundation
- Japan Society for the Promotion of Science (16K15317, 17F17413, 17H05700)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Keywords
- histone deacetylase inhibitors, diketopiperazines, cerebral ischemia, neuronal cell death, neuroprotection, XIAP, Parkinson's disease model, structure-activity relationship
- MeSH terms
- Animals, Benzamides, Cell Line, Brain Ischemia, Humans, Models, Biological, Neurons, Structure-Activity Relationship, Molecular Structure, Cell Death, Neuroprotective Agents, Rats, Diketopiperazines, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: New 5-Aryl-Substituted 2-Aminobenzamide-Type HDAC Inhibitors with a Diketopiperazine Group and Their Ameliorating Effects on Ischemia-Induced Neuronal Cell Death. https://app.cochat.ai/papers/10.1038/s41598-018-19664-9
- The paper
- Hirata, Y., Sasaki, T., Kanki, H., Choong, C.-J., Nishiyama, K., Kubo, G., Hotei, A., Taniguchi, M., Mochizuki, H., & Uesato, S. (2018). New 5-Aryl-Substituted 2-Aminobenzamide-Type HDAC Inhibitors with a Diketopiperazine Group and Their Ameliorating Effects on Ischemia-Induced Neuronal Cell Death. Scientific Reports. https://doi.org/10.1038/s41598-018-19664-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.